Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB

(GEN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed NASDAQ OMX COPENHAGEN - 02/22 10:59:49 am
1069 DKK   -0.79%
02/21EUROPE : Poor results drag European shares down from four-month highs
RE
02/20GLOBAL MARKETS LIVE : Nissan, Lockheed Martin, UBS, Sainsbury...
02/15GENMAB A/S : annual earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
02/18/2019 02/19/2019 02/20/2019 02/21/2019 02/22/2019 Date
1011(c) 990(c) 1008(c) 1077.5(c) 1069(c) Last
112 765 220 939 171 544 654 639 218 532 Volume
-0.30% -2.08% +1.82% +6.89% -0.79% Change
More quotes
Financials (DKK)
Sales 2019 4 296 M
EBIT 2019 1 986 M
Net income 2019 1 734 M
Finance 2019 7 222 M
Yield 2019 -
Sales 2020 5 489 M
EBIT 2020 2 895 M
Net income 2020 2 372 M
Finance 2020 9 857 M
Yield 2020 -
P/E ratio 2019 35,71
P/E ratio 2020 27,47
EV / Sales2019 13,6x
EV / Sales2020 10,2x
Capitalization 65 741 M
More Financials
Company
Genmab specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (47.9%); - income from research and development (44.8%); - other (7. 
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
02/21EUROPE : Poor results drag European shares down from four-month highs
RE
02/20GLOBAL MARKETS LIVE : Nissan, Lockheed Martin, UBS, Sainsbury...
02/15GENMAB A/S : annual earnings release
02/13GENMAB : Announces U.S. FDA Approval of DARZALEX Split Dosing Regimen
AQ
02/12GENMAB : Announces U.S. FDA Approval of DARZALEX® (daratumumab) Split Dosing Reg..
AQ
02/01GENMAB : Announces that the Patent Infringement Lawsuit Relating to DARZALEX is ..
AQ
02/01GENMAB : MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genma..
AQ
01/28EUROPE : Big losses for European stocks as Caterpillar, China disappoint
RE
01/28GENMAB : Announces that the patents asserted against DARZALEX in the United Stat..
AQ
01/28GENMAB : Ad hoc MorphoSys Announces That Its Patents Were Ruled Invalid in Paten..
AQ
More news
Analyst Recommendations on GENMAB
More recommendations
Stock Trading Strategies
GENMAB - 02/07
A good level to buy
BUY
More Stock Trading Analysis
Sector news : Bio Therapeutic Drugs
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06REGENERON PHARMACEUTICALS : 4Q Profit Rises
DJ
02/05U.S. jury orders Takeda to pay Bayer $155 million over haemophilia drug
RE
More sector news : Bio Therapeutic Drugs
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 1 288  DKK
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
Michael K. Bauer SVP, Head-Operations, Research & Development
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Anders Gersel Pedersen Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB0.14%9 991
GILEAD SCIENCES4.80%85 043
VERTEX PHARMACEUTICALS13.49%47 491
REGENERON PHARMACEUTICALS13.51%45 364
SAREPTA THERAPEUTICS INC28.27%9 870
BLUEBIRD BIO INC38.14%7 182